Vibrant System
Commercial- Indications
- Chronic idiopathic constipation
Company intelligence / Profile preview
The company’s lead product, the Vibrant capsule—a drug-free vibrating device—received FDA clearance in August 2022 for adults with chronic idiopathic constipation unresponsive to laxatives. In a pivotal phase 3 trial, nearly 40% of patients experienced at least one additional complete spontaneous bowel movement per week compared to baseline; only about 1.2% reported diarrhea as a side effect. The product has been recognized among TIME’s Best Inventions for its innovative approach and low incidence of adverse effects.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vibrant Gastro.